SecBot SecBot
SECBOTREPLAY Home › Report › ARVN

ARVN · Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the…

Arvinas Inc. · PRESS-RELEASE filed May 1, 2026 at 12:43 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed May 1, 2026 at 12:43 ET

Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-mutated advanced breast cancer after prior endocrine therapy. The approval came ahead of the PDUFA date and is based on the VERITAC-2 trial showing a 43% reduction in risk of disease progression or death vs fulvestrant (HR 0.57). This transformative milestone validates the PROTAC platform and provides a new treatment option for a significant unmet need, though commercial execution and competition remain risks.

  • First FDA-approved PROTAC therapy (VEPPANU/vepdegestrant), approved ahead of June 5, 2026 PDUFA date
  • Indication: ER+/HER2- ESR1-mutated advanced or metastatic breast cancer after ≥1 line of endocrine therapy
  • VERITAC-2 Phase 3 trial (N=270 ESR1m) showed median PFS 5 months vs 2.1 months for fulvestrant (HR 0.57, p=0.0001)
  • Discovered by Arvinas, jointly developed with Pfizer; companies plan to select a third-party partner for commercialization

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access